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Abstract 
Children with unexplained developmental disabilities or congenital anomalies are increasingly being 
referred for genetic diagnostic testing using array-comparative genomic hybridisation (array-CGH) 
and next-generation sequencing (NGS) technologies. Their parents will have to deal with the 
secondary variants that will inevitably arise. We conducted 16 prospective semi-structured interviews 
with native Dutch-speaking parents whose children had undergone clinical array-CGH testing. The 
interviews explored the parents’ experiences, expectations and opinions, specifically regarding the 
communication of results. Concrete examples of “unexpected results” were provided to help guide the 
discussion, differing in severity, treatability, time of onset, level of risk, and carrier status. Data was 
analysed using content and narrative analysis methodologies. Parental motivations for and against the 
disclosure of unexpected results cluster around four main themes: actionability; knowledge; context; 
and characteristics of the result. Most parents wished to know all types of results. Disclosure was 
framed within a holistic, contextual, family-wide view. Genetic counselling should aim to integrate 
explorations of the motivations of parents surrounding the disclosure of results with good clinical 
care. 
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Introduction 
Array-comparative genomic hybridisation (array-CGH) is currently the preferred genetic diagnostic 
test for individuals with unexplained developmental disabilities or congenital anomalies. (1) Array-
CGH and next-generation sequencing (NGS) technologies mark a paradigm shift in terms of the 
amount of genetic data produced and the bioinformatics and other support needed to maximally utilise 
and interpret this data. (2) The shift away from focussed genetic testing also effects a paradigm shift 
in clinical settings.  
One of the most pressing questions in the application of these novel technologies in clinical 
genetics settings is what to do with the secondary variants (also known as incidental findings) that 
will inevitably arise. (3-5) An increasing amount of empirical research is being devoted to this topic. 
(6) This includes the views of patients or their parents. (7-10) As the recipients of genetic test results 
potentially including secondary variants, it is vital that their voices be heard. 
 We interviewed native Dutch-speaking parents whose children had undergone array-CGH 
testing for a diagnosis for their developmental delay with or without dysmorphism or congenital 
anomalies. The interviews covered the experiences, expectations and opinions of parents, specifically 
regarding the communication of results. The term “unexpected result” was used. Although we prefer 
to use “secondary variants” in professional discussions, (11) we found “unexpected result” to be a 
term that parents could more easily understand in interviews. ”Unexpected result” was defined to 
parents as something which the doctor might hypothetically coincidentally find, and distinguished 
from the “expected result”, a diagnosis or explanation for the current clinical condition of their child. 
This article focuses on what motivates parents to want to know or not know secondary variants.  
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Materials and methods 
Participants  
Semi-structured interviews were conducted in Dutch with parents whose children had undergone 
clinical array-CGH testing. None of the parents had received secondary variants. The testing had to 
have been completed and all results (including “no result”) known by the parents; in this way, the 
discussions on secondary variants were completely hypothetical, against a background of experience 
with the return of genetic results. The children had to be under the age of 6 years at the time of 
interview,  to ensure that genetic testing was a recent memory for the interviewees.  
Recruitment was conducted in cooperation with staff of the genetics centre at a single Belgian 
university hospital (co-authors KDV, HP and HVE). Interviews were conducted at home, at a time 
that best suited interviewees. No compensation was offered. Preference was given to couple 
interviews to allow the generation of more comprehensive data and the co-construction of meaning 
during the interview. (12) When it was not possible to interview both parents, the absent parent was 
warmly encouraged to contact the interviewer if they wished to add anything to their partner’s 
answers.  
 
Data collection and analysis 
The interview guide was developed by three authors (GC, KDV, KD) on the basis of two systematic 
reviews conducted previously and clinical experience. (6, 13) The first part of the interview focussed 
on interviewees’ experiences with genetic testing. The second part concerned a discussion of 
secondary variants. The interviewer explicitly emphasised the coincidental or accidental nature of 
secondary variants and the hypothetical nature of the discussion in the case of the interviewees and 
their child. The disclosure of a series of examples of secondary variants was discussed (Figure 1). 
Examples were chosen to represent the wide variety of results possible from the new genetic 
paradigm, (14) not necessarily from array-CGH testing. Interviewees were instructed that such 
secondary variants could be found by new types of genetic testing “such as array-CGH.” A general 
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discussion of secondary variants followed. The third and final part of the interview discussed the 
possible recontacting of the couple if a primary result or secondary variant were discovered years 
later. For more details, see the supplementary online material. 
 The interviews were recorded on tape following consent. Transcripts were analysed using 
NVivo 9 software and content and narrative analysis methodologies. (15-17) The accuracy and 
applicability of codes developed by the interviewer (GC) were checked for one representative 
interview by two co-authors (KDV, KD), and consensus reached. The current article focuses on the 
personal motivations spontaneously provided by interviewees surrounding the disclosure of secondary 
variants. Unless otherwise stated, specific motivations were only raised by a random, nondistinctive 
subsection of parents.  
 
Results 
Study population 
Recruitment took place between March 2012 and June 2013. A total of 26 couples were contacted, 
and 16 interviews were conducted (response rate 62%). While coincidentally none of the couples who 
declined to participate had received a diagnosis through genetic testing, only one explicitly gave this 
as a reason for not participating. Other reasons included lack of time, lack of interest and that an 
interview would be “too confrontational”. The interview guide was not substantially altered after any 
of the interviews. Initial analysis suggested thematic saturation after ten interviews, which the six 
additional interviews confirmed. Due to the father’s work commitments, three interviews were 
conducted with the mother alone, and one interview was conducted with the mother and her mother-
in-law (only the mother’s answers were included for analysis). Interviews lasted approximately 2 
hours (range: 60-162 minutes).  
All of the couples experienced a high degree of uncertainty about the future of their affected 
child, whether or not array-CGH testing had resulted in a diagnosis - understood as a causal genetic 
mutation, previously identified in other cases. This uncertainty was often coupled with loneliness, and 
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stemmed from the fact that their child had a “genetic condition.” All but two of the affected children 
were moderately to severely physically and mentally disabled. Table 1 provides various details about 
the children and their parents.  
 When discussing their experiences with genetic testing and how they would respond to the 
disclosure of secondary variants, it was evident that all couples felt supported by their families and 
genetics centre staff. General satisfaction with genetics centre staff was illustrated for instance in 
discussions about the preferred manner of disclosure. All interviewees answered that they would 
prefer hearing about secondary variants in a face-to-face conversation with their geneticist, especially 
if the secondary variant was considered to be “bad news”. Reasons given included participants’ 
confidence in the geneticist to disclose in a “human” way, open to and able to respond to questions 
about the secondary variant.  
Motivations surrounding the disclosure of secondary variants 
Figure 2 divides the disclosure preferences of parents according to example. Such a graph, only 
displaying the final answers of parents, masks all the discussions and disagreements that took place. 
Some participants changed their position as a result of their own or their partner’s arguments, while 
others became more entrenched in their original position. Most found the questions “difficult”. Many 
openly acknowledged that they seemed to be contradicting themselves. Some opinions and 
motivations were more strongly stated than others.  
The motivations provided by parents supporting their desire to receive secondary variants can 
be grouped around four main themes (Table 2). The themes overlap to some extent, and received 
different emphases depending on the particular example (Table 3).  
Actionability 
The most important group of motivations was actionability; it was always cited in discussions 
of example 1 and returned to in the general discussion at the end. Sometimes discussions on 
actionability would turn to possible prenatal choices. Parents would then often openly acknowledge 
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the apparent paradox of loving their specific disabled child very much and still wishing to have the 
choice to avoid other serious sickness like Duchenne muscular dystrophy (example 2); life was 
difficult enough with one sick child. Some also emphasised the difference between having a 
hypothetical discussion and actually being faced with a concrete, difficult prenatal decision.  
 
Knowledge 
A second theme was knowledge. Some parents said they “just want[ed] to know everything”, 
and were consistent across all examples in favouring disclosure. Others “just want[ed] to know” 
specific examples, and had difficulty explaining why. The motivation of knowing what will happen in 
the future, and the conviction that a given example would impact the future, were cited as motivators 
by various interviewees across all examples. However, the image of a crystal ball was often used to 
put this into perspective: much as some parents might want a “crystal ball” to look into the future, 
they acknowledged that this was unrealistic and possibly undesirable. Additionally, almost all parents 
made a distinction between their interest in secondary variants and targeted findings; when asked if 
they would like the doctor to specifically go looking for particular “secondary variants”, almost all 
said it was unnecessary unless the doctor had some reason to suspect the secondary variant based on 
symptoms or family history. The fact that a test had been carried out and a result found was a reason 
for disclosure; it was clear from the way in which interviewees talked about such a finding that they 
understood that it would only turn up coincidentally, and would not be specifically sought for. The 
theme of knowledge also included sharing the knowledge. For example, most found it unacceptable if 
the doctor would know something and not disclose; this included some who said that they would 
rather the doctor disclose something against their stated will, than that the doctor would know a 
certain unexpected result and not disclose. Some said that if the secondary variant were found in one 
child, they would of course want to know about the other children too. All wanted to share the 
information with other family members if the latter were open. Some made a distinction between 
knowing and then acting on the knowledge, and valued having the choice to know. Knowledge of 
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secondary variants was also appreciated as a way to avoid reproaches or regrets retrospectively. There 
was some concern that the knowledge might get lost if not disclosed immediately to parents.  
 
Context 
A third theme was the context of interviewees, expressed in two main ways: secondary 
variants should be disclosed because of existing relationships with geneticists, the world of genetics, 
and the wider family, that foster expectations of disclosure; secondary variants should be disclosed 
because they already have a disabled child requiring so much careful planning and are caught up in 
the genetic testing treadmill. The idea of the duty or responsibility that parents owe to their children, 
as motivation for wanting to know secondary variants, was framed in the context of parent-child 
relationships, and was cited by various participants across all examples. A related contextual 
argument was “because it’s something about my child”, and a few participants said they would be 
more likely to want disclosure for their child than for themselves.  
 
Secondary Variant Characteristics 
A final group of motivations, mainly mentioned in the general discussions at the end of each 
interview, involved specific characteristics of the secondary variant, such as its seriousness and the 
certainty of developing symptoms. 
The motivations provided by parents supporting their wish not to receive secondary variants 
were more example-specific (Table 3). As everyone wanted to know a secondary variant related to 
child cancer (Figure 2), no motivations not to know were given for example 1. In general, motivations 
against disclosure were the antithesis of the four themes of motivations favouring disclosure (Table 
2): if the actionability of the secondary variant was in doubt; if it was feared that the knowledge may 
have negative consequences, for instance on the ability of the child to “just be a child”; if the context 
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of interviewees decreased the importance of the secondary variant; and specific characteristics of the 
secondary variant including its non-immediacy.  
A few motivations were spontaneously mentioned only by a certain type of parent. It must be 
emphasised that as no parents were explicitly asked about a motivation, it cannot be said that these 
motivations only meant something to parents of a particular type or no parents of the opposite type. 
Only parents who had not (yet) received a diagnosis for their child stated that they would like to know 
so as to not live in ignorance or to understand what has happened once the condition manifested, for 
future children, or if the result was “certain”. Regarding motivations against disclosure, only parents 
who as yet only had one child reasoned that they would not need to know about carrier status because 
their affected child will never have their own children; conversely, only parents who had other, 
healthy children said that they would not need to know about late-onset conditions (specifically 
examples 3 and 4) because the child could ask themselves when they reached majority. 
 
Discussion 
The desire of all parents to want to know a serious and treatable secondary variant that affects 
children and will definitely appear, as in the case of example one, matches recommendations that 
parents not be given the choice to refuse such a secondary variant. (18) However, the interest of the 
majority of parents in other types of secondary variants runs counter to recommendations that only 
serious, clinically actionable findings be disclosed. (19) Participants’ predicted responses to certain 
types of secondary variants are also in conflict with research on the variable uptake of predictive 
testing for late-onset familial conditions or the real impact on behaviour after genetic risk testing. (20-
22) The expectations and views of parents and patients, empirical research on genetic testing, 
professional expertise and evolving guidelines all form complementary facets of research and clinical 
practice. 
Interviewees had a rich understanding of both “serious” and “actionable”. Similar to the views 
of lay participants in other qualitative research, the clinical relevance of a secondary variant was not 
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sufficient as the sole standard for disclosure. (10) Interestingly, the negative emotional responses 
often listed as potential harms of disclosure seldom mentioned in interviews, or participants were 
more inclined to acknowledge that while it would be difficult to hear such a result they still favoured 
disclosure. The direct experiences of interviewees increase the reliability of their predicted emotional 
responses. (23) Furthermore, interviewees considered secondary variants to be something which 
belonged to the whole family, as evidenced by the way in which they discussed the implications of 
examples 3 and 5 and their willingness to share genetic information with the extended family. Support 
for viewing secondary variants of adult-onset conditions in children as family matters can be found in 
some of the recent clinical literature, (24, 25) and is in line with earlier research on the attitudes of 
parents towards testing their children’s cystic fibrosis carrier status. (26) The idea that wider family 
implications might be a reason for caution in disclosure, suggested by some authors, (13) was not a 
concern. Those who had difficulties with some family members said they would just not disclose to 
them; it did not occur to them that this might be a reason to forgo disclosure altogether. 
 The involvement of children in the scenarios was more often an encouragement to want 
disclosure than a deterrent. This may be because most of these children will always be very dependent 
on their parents or other caregivers. It could be said that parents saw themselves as the “gatekeepers” 
of information for their children. (8) The “respect for the open future of the child” concept, so lauded 
in the literature, (27) did not appear to be part of the interviewees’ lives or ways of thinking. It is 
noteworthy that only parents who had other, healthy children said that they would not need to know 
about late-onset conditions because their future adult child could ask themselves; it was as if the other 
parents whose only experience of children was disability could not so readily imagine independent 
grownup children. Parents often referred to their specific context of caring for a disabled child as a 
reason to want to know secondary variants, also remarking that they could imagine that parents of 
healthy children, who do not have to plan their lives around their child’s disability, might be less 
inclined to want to know secondary variants. The specificity of interviewees is a limitation of this 
study. It means that the results may not be generalisable to parents in general. However, parents with 
disabled children will continue to be the first recipients of NGS.  
This article is protected by copyright. All rights reserved 
 
 Our research complements and extends similar research recently published by Sapp et al. (9) 
The current study goes further in including more scenarios, which allowed more motivations to 
surface. We report comparable results for Sapp et al.’s first two secondary variant scenarios 
(examples 1 and 3 here), although a higher degree of interest in carrier status. The reason for this 
discrepancy is unclear, possibly related to cultural differences or the high level of public awareness of 
recessive conditions (Table 3, example 5). Future research could investigate the motivations of those 
who have experience receiving secondary variants.  
 One limitation of the current study is that 80% of the couples were recruited through a 
university hospital. Interviewees thus represent only a certain clinical population. Study participants 
were generally highly educated and articulate, as is common in interview research.  Moreover, given 
that array-CGH testing only provides a diagnosis in up to 17% of cases of unexplained intellectual 
disability, (31) it is unfortunate that a greater proportion of those who have not (yet) received a 
diagnosis did not participate. While it is not possible to discover all of the examples of secondary 
variants discussed in the interviews using array-CGH, the focus of the study was to explore 
hypothetical scenarios made possible by the new genetic testing paradigm, of which array-CGH is an 
example. 
 Sometimes the motivations suggested supporting disclosure were based on inaccurate medical 
knowledge or an overestimation of either the usefulness of the information or its impact on behaviour. 
Counselling should address this. (32) However, counselling discussions should also bear in mind that 
“usefulness” can mean different things to different people. Discussion of the motivations of parents 
and patients, framed within their holistic, contextual view of genetic testing, should be brought 
together with good clinical care. (33) The parents included in this interview study all showed a high 
degree of trust in the scientific and clinical expertise of their geneticists. Such trust is a necessary 
basis for making complex disclosure decisions about genetic secondary variants, and must be 
continually striven for. 
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Figure and table titles and legends 
Figure 1: Examples of secondary variants provided in the interviews for discussion.  
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Figure 2: “Imagine that the doctor accidentally discovered that your child had a gene for X... would 
you want to know?” Some parents changed their minds in the course of the discussion; only their final 
answer (yes, maybe, no) has been counted here. 
Legend for Figure 2:  No        Unsure        Yes 
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Table 1: Socio-demographic details for the interviewees and their children, plus some details on their 
genetic testing experiences. 
Father Mother
Age
25-34 5 9
35-44 10 7
45-54 1 0
Highest study level
Secondary education 7 4
Non-academic tertiary education 5 7
University tertiary education 4 5
Gender of child
Male 6
Female 10
Age of child at first genetics centre visit
< 6 months 6
6 months < child < 1 year 3
1 year < child < 2 years 3
2 years < child < 3 years 4
Position of child in family
First child 6
Second child 5
Third child 5
Time between receiving array-CGH result and interview
< 6 months 8
6 months < x < 1 year 5
1 year < x < 2 years 2
> 3 years 1
Number of genetics centre visits (before interview)
2 visits 6
3 visits 6
4 visits 4
Information about the parents
Information about the child
Miscellaneous
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Table 2: Motivations raised in the interviews surrounding the disclosure of secondary variants. 
Theme Pro-disclosure Anti-disclosure
Actionability Treatment Doubtful actionability
Prevention
Preparation
Knowledge Just want to know (everything) Possible negative consequences
The future
Already been found
Sharing knowledge
To have choices
No regrets/reproaches
Context Existing relationships foster 
disclosure expectations
Decreased importance of the secondary 
variant because of the context
Personal context
Secondary variant characteristics Seriousness Not so serious
Certainty of developing Not a certainty
Non-immediacy
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Table 3: Motivations raised per example surrounding the disclosure of secondary variants, with 
representative quotations. Interviewees are identified as mother/father, gender and age of affected 
child, and whether or not they have received a diagnosis through array-CGH testing (d+/d- 
respectively). Quotations have been translated from Dutch by the bilingual interviewer.  
 
 
Secondary Variant 
Example
Motivations supporting disclosure Representative Quotation Motivations against disclosure Representative Quotation
Actionability to save their child's life; to 
implement earlier screening; to recognise the 
symptoms on time; possibly make reproductive 
choices; to test themselves and their other 
children if appropriate; pass on the information 
to other family members; disclosure would give 
time to prepare, so that the couple would know 
what would happen or could imagine the future 
and make plans appropriately; doctors have a 
duty to disclose based on the result's 
actionability
Knowledge so that there would be no 
unanswered questions or regrets afterwards; 
something you "have" to know;  right as a 
parent to know
Context doctors have a duty to disclose based 
on the doctor-patient (/parent) relationship; the 
example was recognised as something serious 
and difficult that would impact the future, but 
two interviewees discussed how they knew they 
could handle disclosure based on how they 
handled their current situation
Actionability palliative care; possible 
reproductive choices for the couple or their 
other children if applicable; some wanted to 
know this example more than example 1 
precisely because nothing could be done; 
disclosure would allow them to be on time, e.g. 
in recognising the symptoms, or would give 
them time; emphasis on practical and mental 
preparations, e.g. house renovations and 
acceptance of the inevitable
Actionability question of what to do with the 
"extra" time if the doctor were to disclose 
now; given that there is nothing that can 
effectively be done in terms of treatment or 
prevention, the couple might just spend the 
time worrying or depressed, which would 
have an unwanted negative effect on the 
children
Knowledge know now to be ready for when 
prevention or treatment would be possible; to 
avoid the regret of not treating the child 
appropriately, e.g. to not interpret as 
"misbehaviour" what is part of the illness, or to 
be able to give the sick child the help they need; 
to make the most of the time remaining; so that 
the information would not get lost; knowledge 
would allow the couple to make choices; duty 
of the doctor to disclose
Knowledge sometimes it is just better not to 
know; unrealistic to think that knowing now 
would enable one to make the most of the 
time remaining; if the medical experts 
advised against it
Secondary variant characteristics the 
inevitability of the appearance of symptoms
Secondary variant characteristics the 
inevitability of the appearance of symptoms 
without being able to do anything; if it was 
going to happen anyway, the couple could 
just wait
Actionability earlier screening; concern that the 
symptoms of early-onset Alzheimer's disease 
could easily go unrecognised; need to prepare 
the child's environment in cases where the child 
would always need specialised care anyway due 
to their disabilities; good to be given the time to 
learn how to cope with someone with 
Alzheimer's disease; participants would regret 
not being given the chance to plan their lives 
accordingly; knowing would motivate them to 
improve their quality of life, and they would 
encourage their child to live differently
Actionability question of what to do with the 
"extra" time if the doctor were to disclose 
now; concern of negatively impacting the 
child's adult future, possibly through 
insurance coverage disadvantages; those 
who believed the symptoms would be easily 
recognisable did not have to know
Knowledge parents would need to know this 
secondary variant about their child in order to 
get themselves tested; the only scenario where 
one parent used the phrase "right of the child to 
know"; in order to have a realistic image of the 
child's future; "the more you know the better"; 
"why not [know]?"
Knowledge concern that the knowledge 
might rob their child of opportunities they 
would otherwise have taken, which would 
then be a source of regret
Example 3: An adult 
disease that will 
definitely appear and 
that cannot be 
definitively treated 
e.g. early-onset 
Alzheimer’s disease 
(as opposed to late-
onset Alzheimer’s 
... That you know it, because by 
the time that the doctors have 
actually done all the tests so they 
know what it is, but if you already 
know “that’ll be the cause”, you 
can win lots of time and know 
how to cope... ... Maybe you 
could take a course about “how 
to cope with a 40 year old with 
Alzheimer’s.” It’s true, you 
know? That can take away lots of 
frustrations, I think. (mother, girl 
3 years, d+)
But then that child will maybe 
never get married, never have 
children. He’ll always have 
that... as a family you’ll always 
have that in the back of your 
head. You might rob him of 
opportunities, I think. (mother, 
boy 2 years, d-)
Example 1: A serious 
disease that affects 
children, that will 
definitely appear and 
that can be treated 
e.g. a heritable form 
of child cancer
Of course [I’d want to know]. Me 
anyway. And certainly if it can be 
treated, that there’s something 
you can do, yes. Yeah, I wouldn’t 
know why anyone [wouldn’t want 
to know]... (mother, girl 3 years, 
d+)
(none given) (n/a)
Example 2: A serious 
disease that affects 
children, that will 
definitely appear but 
which cannot be 
treated or prevented 
e.g. Duchenne 
muscular dystrophy, a 
nerve disease
... to be prepared to... “mourn” is 
a big word <laugh> but I mean 
also maybe the right word, more 
to learn to live with it... to 
process it, to be given the time or 
something to process the sickness 
that your child has, that’s why, I 
think, you know? (father, girl 4 
years, d-)
But you could also say, “If you 
know it, then you will live more 
consciously and that will 
increase your quality of life. 
(mother, boy 4 years, d+)                                     
I think that will be of short 
duration. (father)
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Context most of the interviewees were under 
the age of 40 (average age: 36), and this 
example was introduced as becoming relevant 
around that age, so the personal relevance of 
the example was readily apparent; the context 
was seen as the whole family, as the result 
would be important to the whole family; also, 
parents should be told now so that they could 
tell their children when the time came (though 
there was much discussion about how and 
when disclosure to the child should take place), 
and so that the parents would be able to look for 
support from the wider family
Secondary variant characteristics non-life 
threatening, non-physical, something that 
would happen in the distant future
Actionability possible prevention; timely 
recognition; management of symptoms; many 
were convinced both of the actionability of this 
secondary variant and its impact on their 
lifestyle and behaviour
Actionability worry that the information 
might cause parents to over-react, treating 
their child differently when it may not be 
necessary or prevention may not be 
completely reliable; scepticism that knowing 
would cause them to change their behaviour 
drastically - either they were already 
involved in regular check-ups or healthy 
eating, or they doubted that the secondary 
variant would help
Knowledge know now to allow the choice to 
change behaviour, and to allow parents to pass 
on the information to their children, thus giving 
them the choice too; parents could then get 
informed about the condition and the latest 
research; one more piece of possibly useful 
medical information
Context the fact of knowing people, 
including top sportspeople, who had 
diabetes and could cope with it; viewed as a 
common condition; could wait to receive the 
information from the family doctor before 
starting prevention; one interviewee (who 
also had older children besides the affected 
child) mentioned the fact that symptoms 
only appear in adulthood, and she might 
want to know about herself but not about 
her children
Context the information would carry more 
weight if it came from a geneticist rather than a 
general practitioner; those with a family history 
of diabetes were interested in the information 
because they knew the condition's impact; 
considered to be a condition whose severity is 
often underestimated
Secondary variant characteristics only an 
increased risk, not a certainty, and this was 
set against a context of risk information in 
general
Actionability to then test partners and other 
family members for their carrier status; a few 
who had no plans to have more children still 
expressed a desire to subsequently test their 
own carrier status, either just of curiosity or to 
be able to tell the child later; so that their child 
and the child's future partner would get the 
chance to know and be able to explore their 
reproductive options; to be able to look after the 
child once they were told the information later
Actionability the uncertain likelihood that 
the secondary variant would have 
consequences, either because their affected 
child would never be able to have children 
of their own, or because it was only a 
chance that two carriers will meet each other
(All but three interviewees 
wanted to know this secondary 
variant)
Context parents felt it was important for their 
child to know their carrier status and explore 
their reproductive options precisely because 
they knew how difficult it can be with a 
disabled child; many participants were familiar 
with cystic fibrosis through friends, colleagues, 
or recent local media attention in documentaries 
and films, and viewed the secondary variant as 
potentially serious information; others saw no 
harm in knowing because it was "just 
information" and not as drastic as some of the 
earlier examples
Example 5: carrier of 
e.g. cystic fibrosis
... so that at that moment you can 
say to your child look, voila, you 
have the choice, keep it in mind, 
it could happen, get informed, but 
make your own choice, because I 
don’t think that we as parents 
have the right to say, you’re not 
allowed to have any children or 
whatever, I mean, but look, here 
is the information, go to the 
geneticist. (mother, girl 3 years, 
d+)
onset Alzheimer’s 
disease)
Example 4: A risk 
factor, with certain 
preventative 
behavioural changes 
possible, e.g. an 
increased risk of type 
II diabetes (as 
opposed to type I 
diabetes)
Of course! There are all sorts of 
things you can do! (father, boy 1 
year, d+)
Plus it is only the chance that 
you’ll get it, right? If you have to 
start taking into account all the 
things that you possibly could 
get, then you might as well never 
go outside, never go in the sun 
because then you might get skin 
cancer, you might as well never 
do sport because then you might 
get asthma... I think the main 
thing is to keep living in a good 
way. (father, girl 4 years, d-)
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